Evidence map›Paper›PMID 25925377›Full record

ArticleNeoplasia (New York, N.Y.)2015

Widespread Non-Canonical Epigenetic Modifications in MMTV-NeuT Breast Cancer.

Sara J Felts, Virginia P Van Keulen, Michael J Hansen, Michael P Bell, Kathleen Allen, Alem A Belachew, Richard G Vile, Julie M Cunningham, Tanya L Hoskin, V Shane Pankratz and 1 more

Open access · goldAbstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Breaking tolerance with engineered class I antigen-presenting molecules.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Sara J FeltsDepartment of Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Virginia P Van KeulenDepartment of Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Michael J HansenDepartment of Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Michael P BellDepartment of Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Kathleen AllenDepartment of Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Alem A BelachewDepartment of Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Richard G VileDepartment of Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA; Department of Molecular Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA.
Julie M CunninghamDepartment of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Tanya L HoskinDepartment of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA.
V Shane PankratzDepartment of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA.
Larry R PeaseDepartment of Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA; Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN, USA. Electronic address: pease.larry@mayo.edu.
Mayo Clinic · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI Fergus Joseph Couch · 2005 to 2026
$49.9M
NCI NIH HHS N01 CA015083NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA116201
6 · The paper itself

Abstract

Breast tumors in (FVB × BALB-NeuT) F1 mice have characteristic loss of chromosome 4 and sporadic loss or gain of other chromosomes. We employed the Illumina GoldenGate genotyping platform to quantitate loss of heterozygosity (LOH) across the genome of primary tumors, revealing strong biases favoring chromosome 4 alleles from the FVB parent. While allelic bias was not observed on other chromosomes, many tumors showed concerted LOH (C-LOH) of all alleles of one or the other parent on sporadic chromosomes, a pattern consistent with cytogenetic observations. Surprisingly, comparison of LOH in tumor samples relative to normal unaffected tissues from these animals revealed significant variegated (stochastic) deviations from heterozygosity (V-LOH) in every tumor genome. Sequence analysis showed expected changes in the allelic frequency of single nucleotide polymorphisms (SNPs) in cases of C-LOH. However, no evidence of LOH due to mutations, small deletions, or gene conversion at the affected SNPs or surrounding DNA was found at loci with V-LOH. Postulating an epigenetic mechanism contributing to V-LOH, we tested whether methylation of template DNA impacts allele detection efficiency using synthetic oligonucleotide templates in an assay mimicking the GoldenGate genotyping format. Methylated templates were systematically over-scored, suggesting that the observed patterns of V-LOH may represent extensive epigenetic DNA modifications across the tumor genomes. As most of the SNPs queried do not contain standard (CpG) methylation targets, we propose that widespread, non-canonical DNA modifications occur during Her2/neuT-driven tumorigenesis.

Indexed as

AllelesAnimalsBreast NeoplasmsCell Transformation, NeoplasticEpigenesis, GeneticFemaleGene FrequencyGenes, Tumor SuppressorGenotypeHeterozygoteLoss of HeterozygosityMiceMice, Inbred BALB CPolymorphism, Single Nucleotide

Identifiers

PMID25925377
PMCPMC4415121
OpenAlexW1814506728

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.